The aim of this study was to investigate whether plasma biomarkers, including p-tau181, p-tau217, Aβ42, Aβ40, and GFAP, can serve as diagnostic tools for distinguishing AD from normal cognition in very elderly individuals. The gene discussed is GFAP; the disease is Alzheimer disease.